JP2010509570A - エクスビボフローサイトメトリーの方法および装置 - Google Patents

エクスビボフローサイトメトリーの方法および装置 Download PDF

Info

Publication number
JP2010509570A
JP2010509570A JP2009535333A JP2009535333A JP2010509570A JP 2010509570 A JP2010509570 A JP 2010509570A JP 2009535333 A JP2009535333 A JP 2009535333A JP 2009535333 A JP2009535333 A JP 2009535333A JP 2010509570 A JP2010509570 A JP 2010509570A
Authority
JP
Japan
Prior art keywords
folate
cells
group
ligand
wavelength
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2009535333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010509570A5 (enExample
Inventor
ロー，フィリップ，エス．
ヒー，ウェイ
クララティン，スミス，エー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of JP2010509570A publication Critical patent/JP2010509570A/ja
Publication of JP2010509570A5 publication Critical patent/JP2010509570A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1429—Signal processing
    • G01N15/1433—Signal processing using image recognition
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
    • G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/1434—Optical arrangements
    • G01N2015/1438—Using two lasers in succession
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2009535333A 2006-11-03 2007-11-02 エクスビボフローサイトメトリーの方法および装置 Ceased JP2010509570A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85666706P 2006-11-03 2006-11-03
US95656207P 2007-08-17 2007-08-17
PCT/US2007/023176 WO2008057437A2 (en) 2006-11-03 2007-11-02 Ex vivo flow cytometry method and device

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014144399A Division JP2014238406A (ja) 2006-11-03 2014-07-14 エクスビボフローサイトメトリーの方法および装置

Publications (2)

Publication Number Publication Date
JP2010509570A true JP2010509570A (ja) 2010-03-25
JP2010509570A5 JP2010509570A5 (enExample) 2012-01-12

Family

ID=39365074

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009535333A Ceased JP2010509570A (ja) 2006-11-03 2007-11-02 エクスビボフローサイトメトリーの方法および装置
JP2014144399A Pending JP2014238406A (ja) 2006-11-03 2014-07-14 エクスビボフローサイトメトリーの方法および装置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014144399A Pending JP2014238406A (ja) 2006-11-03 2014-07-14 エクスビボフローサイトメトリーの方法および装置

Country Status (5)

Country Link
US (2) US8685752B2 (enExample)
EP (1) EP2087337A4 (enExample)
JP (2) JP2010509570A (enExample)
CA (1) CA2668197A1 (enExample)
WO (1) WO2008057437A2 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58102538A (ja) * 1981-12-14 1983-06-18 Fujitsu Ltd 半導体装置の製造方法
JP2013104876A (ja) * 2011-11-14 2013-05-30 Leica Microsystems Cms Gmbh 試料における励起状態の寿命を測定するための方法
JP2013117529A (ja) * 2011-12-01 2013-06-13 Leica Microsystems Cms Gmbh 試料を検査するための方法および機器
JP2018535925A (ja) * 2015-09-09 2018-12-06 オン ターゲット ラボラトリーズ エルエルシー Ｐｓｍａ標的化ｎｉｒ色素およびその使用
JP2019138838A (ja) * 2018-02-14 2019-08-22 住友ゴム工業株式会社 特定細胞捕捉方法
US11360078B2 (en) 2016-09-29 2022-06-14 Sumitomo Rubber Industries, Ltd. Medical analysis device and cell analysis method
US11573232B2 (en) 2018-02-14 2023-02-07 Sumitomo Rubber Industries, Ltd. Method for capturing specific cells
US11614440B2 (en) 2019-01-24 2023-03-28 Sumitomo Rubber Industries, Ltd. Specific cell fractionating and capturing methods

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2316349C2 (ru) * 2001-05-02 2008-02-10 Пердью Рисерч Фаундейшн Лечение и диагностика заболеваний, опосредованных макрофагами
US8043602B2 (en) * 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
CA2527196C (en) 2003-05-30 2012-10-16 Purdue Research Foundation Diagnostic method for atherosclerosis
US20050232919A1 (en) 2004-02-12 2005-10-20 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
ES2731448T3 (es) * 2004-12-23 2019-11-15 Purdue Research Foundation Procedimiento de análisis por imagen mediante tomografía por emisión de positrones
JP2009521206A (ja) 2005-04-22 2009-06-04 モルフォテック、インク． 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
WO2007006041A2 (en) 2005-07-05 2007-01-11 Purdue Research Foundation Imaging and therapeutic method using monocytes
WO2007038346A2 (en) 2005-09-23 2007-04-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
US8685752B2 (en) 2006-11-03 2014-04-01 Purdue Research Foundation Ex vivo flow cytometry method and device
JP5869205B2 (ja) 2007-02-07 2016-02-24 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ ポジトロン放射断層画像法
CN101678124A (zh) 2007-03-14 2010-03-24 恩多塞特公司 结合配体连接的微管溶素递药缀合物
US8961926B2 (en) * 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
EP3569251A1 (en) 2007-06-25 2019-11-20 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
EP2921482B1 (en) * 2007-06-26 2018-09-05 The Johns Hopkins University Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents
AU2015203742B2 (en) * 2007-06-26 2016-12-01 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2010039802A2 (en) * 2008-09-30 2010-04-08 Northwestern University Methods and compositions for isolating nucleic acid
WO2010045598A2 (en) * 2008-10-17 2010-04-22 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
US20120003151A1 (en) * 2009-03-05 2012-01-05 Purdue Research Foundation Method for early imaging of atherosclerosis
US12083191B2 (en) 2009-10-19 2024-09-10 Case Western Reserve University Composition and methods for imaging cells
WO2011099565A1 (ja) * 2010-02-10 2011-08-18 シスメックス株式会社 血液中癌細胞の検出方法及びそれに用いるプログラム
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US10363309B2 (en) 2011-02-04 2019-07-30 Case Western Reserve University Targeted nanoparticle conjugates
ES2930651T3 (es) * 2011-09-06 2022-12-20 Becton Dickinson Co Métodos y composiciones para la detección citométrica de células tumorales circulantes en una muestra
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
JP6208473B2 (ja) 2012-06-20 2017-10-04 アークレイ株式会社 血液成分を含む試料の処理方法
KR20150070318A (ko) 2012-10-16 2015-06-24 엔도사이트, 인코포레이티드 비천연 아미노산을 함유하는 약물 전달 컨쥬게이트 및 사용 방법
EP3858341A1 (en) 2012-11-15 2021-08-04 Endocyte, Inc. Psma ligand-containing conjugates for the treatment of prostate cancer
ES2776698T3 (es) 2012-12-20 2020-07-31 Purdue Research Foundation Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
CN103073538B (zh) * 2012-12-31 2015-05-20 中国食品药品检定研究院 1,4 - 二氢吡啶衍生物作为no荧光探针的用途
US12465651B2 (en) 2013-02-15 2025-11-11 Case Western Reserve University Photodynamic therapy composition
US9889199B2 (en) 2013-02-15 2018-02-13 Case Western Reserve University PSMA ligands and uses thereof
US11975074B2 (en) 2013-02-15 2024-05-07 Case Western Reserve University Photodynamic therapy composition
US10207005B2 (en) 2013-02-15 2019-02-19 Case Western Reserve University Photodynamic therapy composition
US20170232119A1 (en) 2013-03-15 2017-08-17 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
EP2968335B1 (en) 2013-03-15 2019-03-27 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
US10434194B2 (en) 2013-06-20 2019-10-08 Case Western Reserve University PSMA targeted nanobubbles for diagnostic and therapeutic applications
KR101947053B1 (ko) 2013-10-18 2019-02-12 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원（ｐｓｍａ）의 표지된 억제제, 조영제로서의 이의 용도 및 전립선암 치료용 약제
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
US9709556B2 (en) 2013-12-11 2017-07-18 Analiza, Inc. Devices and methods for determining and/or isolating circulating cancer cells
US20150160246A1 (en) 2013-12-11 2015-06-11 Analiza, Inc. Devices and methods for determining and/or isolating cells such as circulating cancer or fetal cells
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US20160223557A1 (en) * 2015-02-04 2016-08-04 Oregon Health & Science University Method of isolating circulating tumor cells
US20180303830A1 (en) * 2015-06-22 2018-10-25 Thomas Jefferson University Cancers expressing ccr5 and methods of treatment of same
KR102233726B1 (ko) 2015-09-30 2021-03-31 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원（psma)의 18f-태그된 저해제 및 전립선암에 대한 조영제로서 이의 용도
JP7282521B2 (ja) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Ｃａｒ ｔ細胞療法のための方法および組成物
CN106279212B (zh) * 2016-08-01 2019-06-18 康宏耀源（天津）科技有限公司 以叶酸为靶向基团的光敏药物的合成和应用
US20180036312A1 (en) * 2016-08-02 2018-02-08 ISI Life Sciences Inc. Novel Scaffolds for Intracellular Compound Delivery for the Detection of Cancer Cells
WO2018026965A1 (en) 2016-08-02 2018-02-08 Isi Life Sciences, Inc. Compositions and methods for detecting cancer cells in a tissue sample
US10239891B2 (en) * 2017-05-15 2019-03-26 Indicator Systems International, Inc. Compositions to detect remnant cancer cells
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
US10753942B2 (en) 2017-05-15 2020-08-25 Indicator Systems International, Inc. Methods to detect remnant cancer cells
EP3845902B1 (en) * 2017-06-23 2022-09-14 NanoTemper Technologies GmbH Methods for measuring inter- and/or intra-molecular interactions
CN112292138A (zh) 2018-01-22 2021-01-29 西雅图儿童医院（Dba西雅图儿童研究所） Car t细胞的使用方法
SG11202007426XA (en) 2018-02-06 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
CA3097381A1 (en) 2018-04-17 2019-10-24 Endocyte, Inc. Methods of treating cancer
US12133901B2 (en) 2019-01-18 2024-11-05 Case Western Reserve University PSMA ligand targeted compounds and uses thereof
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
EP4114415A1 (en) 2020-03-06 2023-01-11 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
WO2023086833A1 (en) 2021-11-09 2023-05-19 Case Western Reserve University Psma targeted conjugate compounds and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11287799A (ja) * 1997-11-22 1999-10-19 Stephen C Wardlaw 全血中の異常な有核細胞の検出、同定、計数及び確認方法
JP2002503814A (ja) * 1998-02-12 2002-02-05 イムニベスト・コーポレイション 循環ガン細胞の迅速かつ効率的な単離のための方法および試薬
JP2004511250A (ja) * 2000-10-16 2004-04-15 ギリード・サイエンシズ・インコーポレーテッド 前立腺特異的膜抗原に対する核酸リガンド
JP2004530678A (ja) * 2001-05-02 2004-10-07 パーデュー・リサーチ・ファウンデーション マクロファージが仲介する疾患の治療および診断
JP2005519078A (ja) * 2002-02-27 2005-06-30 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション 急性骨髄性白血病の治療方法
WO2005116234A2 (en) * 2004-04-16 2005-12-08 University Of Massachusetts Detection and quantification of intracellular pathogens
WO2006034046A2 (en) * 2004-09-17 2006-03-30 The Regents Of The University Of Michigan Quantitative two-photon flow cytometry

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2816110A (en) 1956-11-23 1957-12-10 Merck & Co Inc Methods for the production of substituted pteridines
US4713249A (en) 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
US5140104A (en) 1982-03-09 1992-08-18 Cytogen Corporation Amine derivatives of folic acid analogs
US4577636A (en) 1982-11-23 1986-03-25 The Beth Israel Hospital Association Method for diagnosis of atherosclerosis
US5266333A (en) 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US4817601A (en) 1985-03-06 1989-04-04 C. R. Bard, Inc. Catheter system for controlled removal by radiant energy of biological obstructions
US4641650A (en) 1985-03-11 1987-02-10 Mcm Laboratories, Inc. Probe-and-fire lasers
US4718417A (en) 1985-03-22 1988-01-12 Massachusetts Institute Of Technology Visible fluorescence spectral diagnostic for laser angiosurgery
US4850351A (en) 1985-05-22 1989-07-25 C. R. Bard, Inc. Wire guided laser catheter
US4917084A (en) 1985-07-31 1990-04-17 C. R. Bard, Inc. Infrared laser catheter system
NZ217821A (en) 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US5336506A (en) 1986-07-03 1994-08-09 Advanced Magnetics Inc. Targeting of therapeutic agents using polysaccharides
EP0273085A1 (en) 1986-12-29 1988-07-06 IntraCel Corporation A method for internalizing nucleic acids into eukaryotic cells
US4785806A (en) 1987-01-08 1988-11-22 Yale University Laser ablation process and apparatus
CA1340527C (en) 1988-05-31 1999-05-04 Lidia Vallarino Macrocyclic complexes of yttrium, the lanthanides and the actinides having peripheral coupling functionalities
EP0449883B1 (en) 1988-12-21 1996-01-31 Massachusetts Institute Of Technology A method for laser induced fluorescence of tissue
US5688488A (en) 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5094848A (en) 1989-06-30 1992-03-10 Neorx Corporation Cleavable diphosphate and amidated diphosphate linkers
US5753631A (en) 1990-06-15 1998-05-19 Cytel Corporation Intercellular adhesion mediators
AU8007791A (en) 1990-06-15 1992-01-07 Cytel Corporation Intercellular adhesion mediators
RU2123338C1 (ru) 1990-06-15 1998-12-20 Сайтел Корпорейшн Фармацевтическая композиция на основе медиатора межклеточной адгезии (варианты), способ ингибирования межклеточной адгезии, способ лечения воспалительного заболевания, способ анализа тестируемого соединения на способность ингибировать клеточную адгезию, способ получения соединения
US5576305A (en) 1990-06-15 1996-11-19 Cytel Corporation Intercellular adhesion mediators
US5219548A (en) 1990-10-01 1993-06-15 Board Of Regents, The University Of Texas System High affinity halogenated-tamoxifen derivatives and uses thereof
US5275594A (en) 1990-11-09 1994-01-04 C. R. Bard, Inc. Angioplasty system having means for identification of atherosclerotic plaque
JP2774378B2 (ja) 1991-02-08 1998-07-09 ダイアテク，インコーポレイテッド 映像用テクネチウム−９９ｍ標識化ポリペプチド
US5399338A (en) 1991-05-01 1995-03-21 University Of New Mexico Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US5159079A (en) 1991-12-20 1992-10-27 Eli Lilly And Company 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids
US5217456A (en) 1992-02-24 1993-06-08 Pdt Cardiovascular, Inc. Device and method for intra-vascular optical radial imaging
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5759546A (en) 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US6217847B1 (en) 1994-07-01 2001-04-17 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
FI98765C (fi) 1995-01-16 1997-08-11 Erkki Soini Virtaussytometrinen menetelmä ja laite
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US5547668A (en) 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
AU2610097A (en) 1996-04-10 1997-10-29 Sangstat Medical Corporation Cytomodulating conjugates of members of specific binding pairs
RU2101703C1 (ru) 1996-05-29 1998-01-10 Саратовский научно-исследовательский институт травматологии и ортопедии Способ определения наличия активности воспалительного процесса при ревматоидном артрите
US6083480A (en) 1997-05-01 2000-07-04 Diatide, Inc. Calcitonin receptor binding reagents
KR20010041010A (ko) 1998-02-17 2001-05-15 메다렉스, 인코포레이티드 Ｆｃ 수용체 리간드를 사용하여 마크로파지 매개 질환을치료하고 진단하는 방법
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6589503B1 (en) 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US6507747B1 (en) 1998-12-02 2003-01-14 Board Of Regents, The University Of Texas System Method and apparatus for concomitant structural and biochemical characterization of tissue
WO2000047998A1 (en) 1999-02-10 2000-08-17 Cell Works Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
US6167297A (en) 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
US6323313B1 (en) 1999-06-01 2001-11-27 The University Of Washington Annexin derivative with endogenous chelation sites
AU7123500A (en) 1999-09-08 2001-07-09 Sloan-Kettering Institute For Cancer Research Polysialic acid-klh conjugate vaccine
IL131887A0 (en) 1999-09-14 2001-03-19 Dpharm Ltd Phospholipid prodrugs of anti-proliferative drugs
US6782289B1 (en) 1999-10-08 2004-08-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and apparatus for characterizing lesions in blood vessels and other body lumens
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
NO314537B1 (no) 1999-12-06 2003-04-07 Anticancer Therapeutic Inv Sa Reseptorbindende konjugater
CN102805868A (zh) 2000-03-31 2012-12-05 普渡研究基金会 用配体-免疫原缀合物治疗的方法
IL153218A0 (en) 2000-06-02 2003-07-06 Univ Texas Ethylenedicysteine (ec) -drug conjugates
US6780984B2 (en) 2000-07-17 2004-08-24 Northwestern University Method for prognosing cancer and the proteins involved
ATE337011T1 (de) * 2001-02-07 2006-09-15 Beth Israel Hospital Modifizierte psma-liganden und deren verwendung
IL157444A0 (en) 2001-02-23 2004-03-28 Bristol Myers Squibb Pharma Co Labeled macrophase scavenger receptor antagonists and diagnostic and pharmaceutical compositions containing the same
DE60231868D1 (de) 2001-04-24 2009-05-20 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
US7381535B2 (en) * 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
EP1496934A4 (en) 2002-04-19 2006-08-02 Endocyte Inc IMPROVED IMMUNOTHERAPY BY ADJUVANT
SI2151250T1 (sl) 2002-05-06 2014-02-28 Endocyte, Inc. Z vitamini ciljana sredstva za slikanje
US20050026866A1 (en) 2002-08-02 2005-02-03 Pawelek John M. Agents and methods for treatment of disease by oligosaccharide targeting agents
CN101985443A (zh) 2002-11-07 2011-03-16 得克萨斯大学体系董事会 乙二半胱氨酸（ec）-药物结合物、组合物及用于组织特异性疾病显像的方法
EP2529758A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
WO2004087068A2 (en) 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use
JP2007526238A (ja) 2003-05-06 2007-09-13 パーデュー・リサーチ・ファウンデーション マクロファージまたは葉酸受容体を標的とする狼瘡治療法
CA2527196C (en) 2003-05-30 2012-10-16 Purdue Research Foundation Diagnostic method for atherosclerosis
WO2005049579A2 (en) 2003-11-13 2005-06-02 Janssen Pharmaceutica N.V. Immobilized n-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets
WO2005067644A2 (en) 2004-01-07 2005-07-28 Ambit Biosciences Corporation Conjugated small molecules
WO2005087275A2 (en) 2004-03-11 2005-09-22 Board Of Regents, The University Of Texas System Metal radiolabeled pet imaging agents
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
US7491502B2 (en) 2004-12-17 2009-02-17 The General Hospital Corporation In vivo flow cytometry system and method
ES2731448T3 (es) 2004-12-23 2019-11-15 Purdue Research Foundation Procedimiento de análisis por imagen mediante tomografía por emisión de positrones
KR101313712B1 (ko) 2005-01-05 2013-10-01 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 이중 영상화 및 방사선화학요법용 접합체: 조성물,제조방법 및 적용
WO2006093991A1 (en) * 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
CN101175757B (zh) 2005-03-16 2012-11-14 恩多塞特公司 蝶酸及其缀合物的合成和纯化
DE102005012554A1 (de) 2005-03-16 2006-09-28 Beiersdorf Ag Kosmetische Zubereitung mit Hyaluronsäure
WO2007001466A2 (en) 2005-06-14 2007-01-04 Kung, Hank, F. Peptidomimetic somatostatin receptor subtype 2 ligands and pet imaging agents
WO2007006041A2 (en) 2005-07-05 2007-01-11 Purdue Research Foundation Imaging and therapeutic method using monocytes
WO2007038346A2 (en) 2005-09-23 2007-04-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
EP3029461B1 (en) 2006-11-01 2017-12-20 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US8685752B2 (en) 2006-11-03 2014-04-01 Purdue Research Foundation Ex vivo flow cytometry method and device
JP5869205B2 (ja) 2007-02-07 2016-02-24 パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ ポジトロン放射断層画像法
US8961926B2 (en) 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
US20090012009A1 (en) 2007-06-01 2009-01-08 Low Philip S Composition and Method for Treating Inflammatory Disease
EP3569251A1 (en) 2007-06-25 2019-11-20 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9193763B2 (en) 2007-08-17 2015-11-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US20120003151A1 (en) 2009-03-05 2012-01-05 Purdue Research Foundation Method for early imaging of atherosclerosis

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11287799A (ja) * 1997-11-22 1999-10-19 Stephen C Wardlaw 全血中の異常な有核細胞の検出、同定、計数及び確認方法
JP2002503814A (ja) * 1998-02-12 2002-02-05 イムニベスト・コーポレイション 循環ガン細胞の迅速かつ効率的な単離のための方法および試薬
US6365362B1 (en) * 1998-02-12 2002-04-02 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
JP2004511250A (ja) * 2000-10-16 2004-04-15 ギリード・サイエンシズ・インコーポレーテッド 前立腺特異的膜抗原に対する核酸リガンド
JP2004530678A (ja) * 2001-05-02 2004-10-07 パーデュー・リサーチ・ファウンデーション マクロファージが仲介する疾患の治療および診断
JP2005519078A (ja) * 2002-02-27 2005-06-30 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション 急性骨髄性白血病の治療方法
WO2005116234A2 (en) * 2004-04-16 2005-12-08 University Of Massachusetts Detection and quantification of intracellular pathogens
WO2006034046A2 (en) * 2004-09-17 2006-03-30 The Regents Of The University Of Michigan Quantitative two-photon flow cytometry

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58102538A (ja) * 1981-12-14 1983-06-18 Fujitsu Ltd 半導体装置の製造方法
JP2013104876A (ja) * 2011-11-14 2013-05-30 Leica Microsystems Cms Gmbh 試料における励起状態の寿命を測定するための方法
JP2013117529A (ja) * 2011-12-01 2013-06-13 Leica Microsystems Cms Gmbh 試料を検査するための方法および機器
JP2018535925A (ja) * 2015-09-09 2018-12-06 オン ターゲット ラボラトリーズ エルエルシー Ｐｓｍａ標的化ｎｉｒ色素およびその使用
US11360078B2 (en) 2016-09-29 2022-06-14 Sumitomo Rubber Industries, Ltd. Medical analysis device and cell analysis method
JP2019138838A (ja) * 2018-02-14 2019-08-22 住友ゴム工業株式会社 特定細胞捕捉方法
JP7170254B2 (ja) 2018-02-14 2022-11-14 住友ゴム工業株式会社 特定細胞捕捉方法
US11573232B2 (en) 2018-02-14 2023-02-07 Sumitomo Rubber Industries, Ltd. Method for capturing specific cells
US11614440B2 (en) 2019-01-24 2023-03-28 Sumitomo Rubber Industries, Ltd. Specific cell fractionating and capturing methods

Also Published As

Publication number Publication date
WO2008057437A2 (en) 2008-05-15
WO2008057437B1 (en) 2008-11-27
US9279813B2 (en) 2016-03-08
CA2668197A1 (en) 2008-05-15
WO2008057437A9 (en) 2008-08-14
WO2008057437A3 (en) 2008-10-16
US20140234866A1 (en) 2014-08-21
US8685752B2 (en) 2014-04-01
JP2014238406A (ja) 2014-12-18
EP2087337A4 (en) 2010-09-08
US20100055735A1 (en) 2010-03-04
EP2087337A2 (en) 2009-08-12

Similar Documents

Publication Publication Date Title
JP2010509570A (ja) エクスビボフローサイトメトリーの方法および装置
CN105228628B (zh) 与用于使肿瘤靶向成像的化合物缀合的氨基酸连接基的合成和组合物
JP4566912B2 (ja) Ｗｔ１ワクチン適応患者の選択方法
CN102326079B (zh) 新型受体结合配体及其在检测具有生物学益处的细胞中的用途
US20230098031A1 (en) Methods for cell imaging
WO2022216449A1 (en) Water-soluble yellow green absorbing dyes
CN113817023B (zh) 一种靶向fgfr4的亲和肽及其应用
US20230417754A1 (en) Near infrared-ii probes as high affinity targeting imaging agents and uses thereof
US8029767B2 (en) Fluorescent membrane intercalating probes and methods for their use
WO2021069000A1 (en) Fluorescent polymer, fluorescent probe and conjugation kit for advanced functional analysis of cells in haematology, immunology and microbiology, method of preparation and use thereof
CN115677833B (zh) 一种针对人表皮细胞生长因子受体2(her2)的肿瘤亲和肽
JP2009524580A (ja) 蛍光性膜インターカレート・プローブおよびその使用方法
Sturzu et al. Rhodamine-marked bombesin: a novel means for prostate cancer fluorescence imaging
Nguyen et al. Dual‐Sensing Nanoreporter for Dynamic and High‐Throughput Monitoring of Immune Checkpoint Inhibitor Responses in Tumor‐Derived Organoids
JP4630015B2 (ja) 細胞分離回収方法および細胞分離チップおよび細胞分離装置
Mazor et al. Europium-labeled epidermal growth factor and neurotensin: novel probes for receptor-binding studies
JP2012524079A (ja) 新規蛍光標識ポリペプチドを用いたバレット食道における異形成の標的検出
Sengupta et al. Tyrosine-based asymmetric urea ligand for prostate carcinoma: Tuning biological efficacy through in silico studies
CN106518965A (zh) 对溶血磷脂酸特异性识别的多肽探针及其制备与应用
CN116410262A (zh) 一种肿瘤亲和肽及其应用
JP2021524576A (ja) がんの診断及び治療のための組成物及び方法
CN111393872B (zh) 紫外光激发荧光染料及其应用
Sturzu et al. Novel bourgeonal fragrance conjugates for the detection of prostate cancer
US20060281104A1 (en) Leuco dye particles and uses thereof
CZ2019627A3 (cs) Fluorescenční polymer, fluorescenční sonda a konjugační sada pro pokročilé funkční analýzy buněk v hematologii, imunologii a mikrobiologii, způsob jejich přípravy a jejich použití

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120313

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20120314

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120618

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120620

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120810

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130702

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130802

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130902

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140714

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141216

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20150421